EUVIMEDEUVIMED entdecken
Fallbericht

Eculizumab Successfully Rescues Against de novo Atypical Hemolytic Uremic Syndrome Following Retransplantation

Meisi Li, Jiqiu Wen, Jianhui Dong, Ning Wen, Xuyong Sun

Transplantation Proceedings · 2026

DOI: 10.1016/j.transproceed.2026.02.023 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Transplantation Proceedings, 2026. Verfasst von Meisi Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Transplant Medicine, The Second Affiliated Hospital of Guangxi Medical University, Guangxi Clinical Research Center for Organ Transplant…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Atypical Hemolytic Uremic Syndrome, Kidney Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Guangxi Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney transplantation has emerged as the optimal treatment for end-stage renal disease. However, the occurrence of atypical hemolytic uremic syndrome (aHUS) following renal transplantation is extremely uncommon and associated with adverse outcomes, often resulting in early graft loss, thus warranting heightened awareness. This report details a case of successful management of a patient who developed post-transplant aHUS following retransplantation. The patient had previously suffered graft failure shortly after the first kidney transplantation due to unexplained non-rejection mechanisms. Following the second transplantation, the individual presented with new-onset anemia, thrombocytopenia, acute kidney injury, and elevated lactate dehydrogenase levels within a short time frame, all manifesting undetermined etiology. A comprehensive assessment of dynamic changes in hemoglobin, platelet count, serum creatinine, and lactate dehydrogenase, alongside pathological examinations, culminated in a definitive diagnosis of aHUS. After undergoing four treatments with eculizumab, there was a sustained improvement in hemoglobin, platelet count, serum creatinine, and lactate dehydrogenase levels, thereby preserving the function of the transplanted kidney. Timely diagnosis and early application of eculizumab in treating aHUS are crucial. Furthermore, comprehensive pre-transplant evaluations of patients to exclude aHUS risk factors are essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAtypical Hemolytic Uremic SyndromeKidney TransplantationHumansMaleReoperationTreatment OutcomeYoung AdultMiddle Aged

Substanzen

Antibodies, Monoclonal, Humanizedeculizumab

Autor:innen und Institutionen

  • Institute of Transplant Medicine, The Second Affiliated Hospital of Guangxi Medical University, Guangxi Clinical Research Center for Organ Transplantation, Guangxi Key Laboratory of Organ Donation and Transplantation, N…

Förderung

  • Guangxi Natural Science Foundation

Zitieren

APA

Li, M., Wen, J., Dong, J., Wen, N., & Sun, X. (2026). Eculizumab Successfully Rescues Against de novo Atypical Hemolytic Uremic Syndrome Following Retransplantation. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2026.02.023

Vancouver

Li M, Wen J, Dong J, Wen N, Sun X. Eculizumab Successfully Rescues Against de novo Atypical Hemolytic Uremic Syndrome Following Retransplantation. Transplantation Proceedings. 2026. doi:10.1016/j.transproceed.2026.02.023

BibTeX
@article{Li2026,
  author = {Li, Meisi and Wen, Jiqiu and Dong, Jianhui and Wen, Ning and Sun, Xuyong},
  title = {Eculizumab Successfully Rescues Against de novo Atypical Hemolytic Uremic Syndrome Following Retransplantation},
  journal = {Transplantation Proceedings},
  year = {2026},
  doi = {10.1016/j.transproceed.2026.02.023}
}
Kostenlos starten →